Evaluation and Treatment for a 20-Year-Old Female with Hair Loss and Normal TSH
Start topical minoxidil 5% (foam or solution) as first-line treatment, and complete additional laboratory workup to identify treatable contributing factors and rule out androgen excess. 1
Immediate Next Steps in Evaluation
Since TSH is normal, proceed with the following mandatory and recommended laboratory tests:
Mandatory Testing
- Androgen assessment 1:
- Total testosterone using high-quality assay (preferably LC/MS or immunoassay with extraction/purification)
- Free testosterone (via equilibrium dialysis, ultracentrifugation, or calculated using SHBG)
- SHBG (sex hormone-binding globulin)
Recommended Additional Testing
The following labs help identify treatable conditions that may impair hair regrowth 1:
- Ferritin (though evidence for treatment benefit is uncertain, many patients with female pattern hair loss [FPHL] have levels <70 ng/mL)
- Vitamin D (25-hydroxyvitamin D) (62% of FPHL patients have low levels)
- Zinc (15% of FPHL patients have deficiency)
- Prolactin
- Complete blood count (to assess for anemia)
Clinical Examination Requirements
Perform a thorough scalp examination looking for 1:
- Pattern of hair loss: Centrifugal expansion in mid-scalp OR frontal accentuation ("Christmas tree" pattern) suggests FPHL
- Scalp inflammation or scarring: Presence suggests alternative diagnoses requiring scalp biopsy
- Hair pull test: Assess for active shedding
- Signs of hyperandrogenism: Hirsutism, acne, or other virilization signs
Consider dermatoscopic examination or scalp biopsy if the diagnosis is unclear or if scarring/inflammatory changes are present 1.
First-Line Treatment
Topical minoxidil 5% is the only treatment with sufficient evidence and should be started immediately 1:
Formulation options:
- 5% foam once daily, OR
- 5% solution twice daily
- (5% foam once daily is equivalent to 2% solution twice daily and has fewer side effects)
Important counseling points:
- Expect transient increased shedding in first 2-8 weeks (telogen hairs shedding to make room for new anagen growth)
- Must use for at least 12 months for optimal results
- Side effects: scalp pruritus/flaking (more common with solution due to propylene glycol), facial hypertrichosis (more common with 5% formulations)
When to Add Systemic Therapy
Add antiandrogen or 5α-reductase inhibitor if 1:
- Severe hair loss, OR
- Evidence of hyperandrogenism (elevated androgens or clinical signs)
Systemic Treatment Options for Reproductive-Age Women
Critical warning: All systemic options are teratogenic and require strict contraception during treatment and for at least 30 days after discontinuation 1.
Preferred options (lowest risk profile):
Spironolactone 100-200 mg/day 1
- Better response in patients with hirsutism or acne
- Requires at least 12 months of treatment
Finasteride 2.5-5 mg/day 1
- Note: 1 mg daily is ineffective in premenopausal women
- Higher doses (2.5-5 mg) show benefit, particularly in hyperandrogenic patients
Not recommended:
Common Pitfalls to Avoid
Don't assume normal TSH rules out all endocrine causes: Androgen excess is common in FPHL and must be evaluated 1
Don't supplement iron/vitamin D/zinc without documented deficiency: Evidence that correction improves hair growth is lacking, even when deficiencies are present 1
Don't use finasteride 1 mg daily in premenopausal women: This dose is ineffective; requires 2.5-5 mg daily 1
Don't delay minoxidil while waiting for lab results: Start treatment immediately as it requires 12+ months to see benefit 1
Don't forget contraception counseling: If systemic antiandrogens or 5α-reductase inhibitors are considered, ensure reliable contraception is in place first 1
Interpretation of Androgen Results
- If testosterone is >2× upper limit of normal: Check DHEAS to rule out adrenal tumor (DHEAS >600 µg/dL suggests adrenal source requiring imaging) 2
- If androgens are normal: Isolated FPHL with normal androgen levels should NOT be considered a sign of hyperandrogenism 1
- If androgens are elevated: Consider PCOS, ovarian hyperthecosis, or androgen-secreting tumor depending on degree of elevation